Eukaryotic initiation factor 4F — sidestepping resistance mechanisms arising from expression heterogeneity

Jennifer Chu, Santiago Ramon y. Cajal, Nahum Sonenberg, Jerry Pelletier

Research output: Contribution to journalReview articleResearchpeer-review

8 Citations (Scopus)

Abstract

© 2017 Elsevier Ltd There is enormous diversity in the genetic makeup and gene expression profiles between and within tumors. This heterogeneity leads to phenotypic variation and is a major mechanism of resistance to molecular targeted therapies. Here we describe a conceptual framework for targeting eukaryotic initiation factor (eIF) 4F in cancer — an essential complex that drives and promotes multiple Cancer Hallmarks. The unique nature of eIF4F and its druggability bypasses several of the heterogeneity issues that plague molecular targeted drugs developed for cancer therapy.
Original languageEnglish
Pages (from-to)89-96
JournalCurrent Opinion in Genetics and Development
Volume48
DOIs
Publication statusPublished - 1 Feb 2018

Fingerprint

Dive into the research topics of 'Eukaryotic initiation factor 4F — sidestepping resistance mechanisms arising from expression heterogeneity'. Together they form a unique fingerprint.

Cite this